Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in …

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca ...

Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca ...
The New York Times

Book Review

Fifty years after her death, the German-born political thinker has been enshrined as a prophet for our times. What did she actually say? By Jennifer Szalai Need the perfect holiday gift? Try one of ...
NPR

Books

November 24, 2025 • Our annual reading guide returns with 380+ new titles handpicked by NPR staff and trusted critics. Find 13 years of recommendations all in one place — that's more than 4,000 great ...